Last $6.64 USD
Change Today +0.12 / 1.84%
Volume 6.1M
MNKD On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 5:20 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

mannkind corp (MNKD) Snapshot

Open
$6.50
Previous Close
$6.52
Day High
$6.75
Day Low
$6.45
52 Week High
06/30/14 - $11.48
52 Week Low
03/31/14 - $3.80
Market Cap
2.7B
Average Volume 10 Days
5.5M
EPS TTM
$-0.51
Shares Outstanding
405.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MANNKIND CORP (MNKD)

mannkind corp (MNKD) Details

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate is AFREZZA inhalation powder, an insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The company is also developing MedTone and Dreamboat inhaler devices. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

mannkind corp (MNKD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $718.9K
Founder and Executive Chairman
Total Annual Compensation: $824.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $440.8K
Chief Operating Officer
Total Annual Compensation: $459.1K
Corporate Vice President, General Counsel and...
Total Annual Compensation: $387.4K
Compensation as of Fiscal Year 2013.

mannkind corp (MNKD) Key Developments

MannKind Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

MannKind Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company’s net loss applicable to common stockholders was $36.44 million or $0.09 per basic and diluted share compared to net loss to common shareholders of $53.58 million, or $0.16 per basic and diluted share in 2013. Loss from operations was $30,103,000 compared to $46,617,000 a year ago. The net loss applicable to common stockholders for 2014 was $198.4 million or $0.51 per basic and diluted share, slightly higher than the net loss to common shareholders of $191.5 million, or $0.64 per basic and diluted share in 2013. Loss from operations was $179,627,000 compared to $169,401,000 a year ago.

MannKind Corp. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:00 AM

MannKind Corp. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:00 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Hakan S. Edstrom, Chief Executive Officer, President and Director, Matthew J. Pfeffer, Chief Financial Officer, Principal Accounting Officer and Corporate Vice President.

MannKind Corp. to Report Q4, 2014 Results on Feb 24, 2015

MannKind Corp. announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Feb 24, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNKD:US $6.64 USD +0.12

MNKD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MNKD.
View Industry Companies
 

Industry Analysis

MNKD

Industry Average

Valuation MNKD Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MANNKIND CORP, please visit www.mannkindcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.